Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity

NCT03523273 on ClinicalTrials.gov · last registry update 2022-06-23

Finished 31 August 2021, after enrolling 136 people. Primary outcome, as filed: Gastric Emptying of Solids (T1/2). liraglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Michael Camilleri, MD
Sponsor type: Other
Enrollment: 136
Started: 2017-11-29
Primary completion: 2021-08-31 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Gastric Emptying of Solids (T1/2)

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.